Drug Trial Radar · NCT06329661
A Clinical Trial to Evaluate the Corneal Endothelial Health of DED Subjects Treated With Cyclosporine
Last checked: Nov 20, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
204
Actual
Start
Apr 22, 2024
Primary completion
Jul 30, 2025
Study completion Jul 30, 2025
Sponsor
- Lead sponsor
- Novaliq GmbHIndustry
- Sponsor type
- Industry
- First posted
- Mar 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this trial is to evaluate the effect of cyclosporine ophthalmic solution, 0.1% on corneal endothelial cell health in comparison to a hypotonic saline solution in subjects with Dry Eye Disease (DED)
Conditions
- Dry Eye Disease
- Endothelial Cell
Interventions
Cyclosporine ophthalmic solution, 0.1%Drug
Colorless and clear opthalmic solution containing 0.1% Cyclosporine
Saline solution, 0.6%Drug
Colorless and clear sodium chloride solution (0.6%)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Corneal Endothelial Cell Density (ECD)Time frame: 12 months
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
CYS-007 Investigational Site
Newport Beach, California
CYS-007 Investigational Site
Torrance, California
CYS-007 Investigational Site
Garner, North Carolina
CYS-007 Investigational Site
Shelby, North Carolina
CYS-007 Investigational Site
Cranberry Township, Pennsylvania
CYS-007 Investigational Site
Memphis, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.